Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | GRK5 | P34947 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | PRKX | P51817 | 1/20 | 0.34 |
| ▸ | NEK2 | P51955 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.34 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31167609 | 1.00 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1CHEK1ABL1PDGFRB | |
| SCHEMBL17399657 | 0.78 | NOS3 (0.52) | ALDH1A1CHEK1ABL1PDGFRBPDGFRA | |
| SCHEMBL7108696 | 0.77 | KDM4E (0.39) | ALDH1A1USP8POLBKDM4EGAA | |
| SCHEMBL30450356 | 0.77 | KDM4E (0.39) | ALDH1A1USP8POLBKDM4EGAA | |
| SCHEMBL929272 | 0.77 | KMT2A (0.42) | ALDH1A1CHEK1ABL1PDGFRBPDGFRA | |
| SCHEMBL9426003 | 0.77 | USP30 (0.39) | ALDH1A1L3MBTL1CHEK1ABL1PDGFRB | |
| Ammonia Solution, Strong SCHEMBL28870434 | 0.76 | KDM4E (0.38) | ALDH1A1USP8POLBKDM4EGAA | |
| SCHEMBL21928126 | 0.76 | NQO1 (0.39) | ALDH1A1CHEK1ABL1PDGFRBPDGFRA | |
| SCHEMBL2708620 | 0.76 | RPS6KA5 (0.39) | ALDH1A1L3MBTL1CLK4USP8POLB | |
| SCHEMBL24417209 | 0.74 | USP8 (0.36) | ALDH1A1CHEK1ABL1PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076968-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| EP-4034535-B1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-04 | — | — | EP | disclosed |
| US-12544374-B2 | AZA-quinoline compounds and uses thereof | NOVARTIS AG (CH) | 2026-02-10 | — | — | US | disclosed |
| US-20250296939-A1 | BENZOTHIOPHENE COMPOUND | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2025-09-25 | — | — | US | disclosed |
| EP-4516792-A1 | BENZOTHIOPHENE COMPOUND | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2025-03-05 | — | — | EP | disclosed |
| WO-2024009232-A1 | SUBSTITUTED N-(PYRIDIN-2-YL)ACETAMIDE DERIVATIVES AS CDK12/13 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-01-11 | — | — | WO | disclosed |
| WO-2023210740-A1 | BENZOTHIOPHENE COMPOUND | 第一三共株式会社 | 2023-11-02 | — | — | WO | disclosed |
| WO-2023110843-A1 | HETEROBICYCLIC DERIVATIVES AS ITK INHIBITORS | ALMIRALL, S.A. (ES) | 2023-06-22 | — | — | WO | disclosed |
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-09-08 | — | — | US | disclosed |
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-09-08 | — | — | US | disclosed |
| EP-2299816-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-2299816-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2013-11-13 | — | — | EP | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
| EP-2299816-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009155156-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | ALDH1A1 3437/4885L3MBTL1 2263/4885CHEK1 697/4885 |
| US-20250296939-A1 | BENZOTHIOPHENE COMPOUND | NFE2L2, KEAP1, BPTF | ALDH1A1 278/4885L3MBTL1 3259/4885CHEK1 427/4885 |
| US-20260076968-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | EZH2, SUZ12, NR3C1 | ALDH1A1 1941/4885L3MBTL1 1856/4885CHEK1 3282/4885 |
| US-12544374-B2 | AZA-quinoline compounds and uses thereof | EZH2, NR3C1, SUZ12 | ALDH1A1 1524/4885L3MBTL1 2535/4885CHEK1 3267/4885 |
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | EZH2, BMI1, EED | ALDH1A1 808/4885L3MBTL1 3269/4885CHEK1 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.